Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions.
Small interfering RNA (siRNA) that silence genes by the process of RNA interference offers a new therapeutic modality for disease treatment. Polycation-based nanoparticles termed polyplexes have been developed to maximise extracellular and intracellular siRNA delivery, a key requirement for enabling the clinical translation of RNAi-based drugs. Medical applications are dependent on safety; therefore, detailed investigation into potential toxicity to the cell or organism is required. This review addresses potential adverse effects arising from cellular and tissue interactions, immune stimulation and altered gene expression that can be associated with the assembled polyplex or the polycation and siRNA component parts. A greater understanding of the cellular mechanisms involved allows design-based solutions for rationale development of safe, effective and clinically relevant polyplex-based RNAi drugs.
Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark.
Borja
B
Ballarín-González
Kenneth Alan
KA
Howard
D000818:Animals; D015195:Drug Design; D005786:Gene Expression Regulation; D020868:Gene Silencing; D006801:Humans; D007107:Immune System / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics; D053758:Nanoparticles; D011073:Polyamines / Q000009:adverse effects* / Q000737:chemistry; D000071228:Polyelectrolytes; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000009:adverse effects*
D035683:MicroRNAs; D011073:Polyamines; D000071228:Polyelectrolytes; D034741:RNA, Small Interfering